Related Experiment Videos
Anticoagulation and platelet antiaggregation therapy in stroke prevention
1Doris and Stanley Tananbaum Stroke Center, Neurological Institute, New York Presbyterian Hospital, New York, NY 10032, USA. jc1031@columbia.edu
Current Opinion in Neurology
|January 19, 2005
Summary
Choosing antithrombotic therapy for stroke depends on its cause. Warfarin is preferred for atrial fibrillation-related embolism, while antiplatelet agents are favored in other cases due to bleeding risks.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Recent clinical trials have updated understanding of ischemic stroke mechanisms and treatment risks.
- Treatment decisions for stroke are evolving based on new evidence.
Purpose of the Study:
- To review current evidence on antithrombotic therapies for ischemic stroke.
- To guide treatment choices based on stroke etiology and therapeutic risks.
Main Methods:
- Review of recent large clinical trials.
- Analysis of data on anticoagulants and antiplatelet agents.
- Comparison of monotherapy versus combination antithrombotic treatments.
Main Results:
- Warfarin is effective for stroke due to atrial fibrillation-related embolism.
- Warfarin shows no advantage over aspirin for stroke related to intracranial atheroma, patent foramen ovale, or antiphospholipid antibodies.
- Aspirin and clopidogrel have similar recurrent stroke risks; combination therapies often increase bleeding risk without added benefit.
- Aspirin with dipyridamole reduces stroke risk without significantly increasing hemorrhage.
Conclusions:
- Antithrombotic therapy selection must be individualized based on stroke etiology.
- Oral anticoagulation is preferred for cardioembolic stroke in atrial fibrillation.
- Antiplatelet therapy is often favored in other etiologies due to hemorrhage concerns.
- Further research is needed on combination therapies with other agents like antihypertensives and statins.